
  <style>
  .gh-table table { 
    border-collapse: collapse; 
    width: 100%;
    border: 1px solid #444;
    font-size: 12px;
  }
  .gh-table th, .gh-table td { 
    border: 1px solid #444; 
    padding: 4px 6px; 
    vertical-align: top;
    font-weight: 400 !important;   /* regular font */
  }
  .gh-table th { 
    .gh-table th { background: #f5f5f5; text-align: left; }
  }
  .gh-table th { font-weight: 700 !important; }
    @media print {
      .gh-table { font-size: 10px; }
    }
  </style>
  <div class='gh-table'><table><thead><tr><th>record_id</th><th>visit</th><th>Molecola (1)</th><th>Molecola (2)</th><th>description</th></tr></thead><tbody><tr><td>L26</td><td>1</td><td>Acetylsalicylic acid</td><td>Bisoprolol</td><td>Acetylsalicylic acid may decrease the antihypertensive activities of Bisoprolol.</td></tr><tr><td>L26</td><td>1</td><td>Dapagliflozin</td><td>Acetylsalicylic acid</td><td>The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid
is combined with Dapagliflozin.</td></tr><tr><td>L26</td><td>1</td><td>Dapagliflozin</td><td>Bisoprolol</td><td>The therapeutic efficacy of Dapagliflozin can be increased when used in
combination with Bisoprolol.</td></tr><tr><td>L26</td><td>1</td><td>Dapagliflozin</td><td>Gliclazide</td><td>Dapagliflozin may increase the hypoglycemic activities of Gliclazide.</td></tr><tr><td>L26</td><td>1</td><td>Dapagliflozin</td><td>Sacubitril</td><td>The risk or severity of adverse effects can be increased when Dapagliflozin is
combined with Sacubitril.</td></tr><tr><td>L26</td><td>1</td><td>Furosemide</td><td>Acetylsalicylic acid</td><td>The risk or severity of increased serum creatinine can be increased when
Acetylsalicylic acid is combined with Furosemide.</td></tr><tr><td>L26</td><td>1</td><td>Furosemide</td><td>Bisoprolol</td><td>Bisoprolol may increase the hypotensive activities of Furosemide.</td></tr><tr><td>L26</td><td>1</td><td>Furosemide</td><td>Dapagliflozin</td><td>The therapeutic efficacy of Dapagliflozin can be decreased when used in
combination with Furosemide.</td></tr><tr><td>L26</td><td>1</td><td>Furosemide</td><td>Gliclazide</td><td>The therapeutic efficacy of Gliclazide can be decreased when used in combination
with Furosemide.</td></tr><tr><td>L26</td><td>1</td><td>Furosemide</td><td>Sacubitril</td><td>The risk or severity of adverse effects can be increased when Furosemide is
combined with Sacubitril.</td></tr><tr><td>L26</td><td>1</td><td>Furosemide</td><td>Tenofovir alafenamide</td><td>The serum concentration of Tenofovir alafenamide can be increased when it is
combined with Furosemide.</td></tr><tr><td>L26</td><td>1</td><td>Gliclazide</td><td>Acetylsalicylic acid</td><td>The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid
is combined with Gliclazide.</td></tr><tr><td>L26</td><td>1</td><td>Gliclazide</td><td>Bisoprolol</td><td>The therapeutic efficacy of Gliclazide can be increased when used in combination
with Bisoprolol.</td></tr><tr><td>L26</td><td>1</td><td>Insulin degludec</td><td>Acetylsalicylic acid</td><td>The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid
is combined with Insulin degludec.</td></tr><tr><td>L26</td><td>1</td><td>Insulin degludec</td><td>Bisoprolol</td><td>The therapeutic efficacy of Insulin degludec can be increased when used in
combination with Bisoprolol.</td></tr><tr><td>L26</td><td>1</td><td>Insulin degludec</td><td>Dapagliflozin</td><td>The risk or severity of hypoglycemia can be increased when Insulin degludec is
combined with Dapagliflozin.</td></tr><tr><td>L26</td><td>1</td><td>Insulin degludec</td><td>Furosemide</td><td>The risk or severity of hypoglycemia can be increased when Furosemide is
combined with Insulin degludec.</td></tr><tr><td>L26</td><td>1</td><td>Insulin degludec</td><td>Gliclazide</td><td>The risk or severity of hypoglycemia can be increased when Gliclazide is
combined with Insulin degludec.</td></tr><tr><td>L26</td><td>1</td><td>Liraglutide</td><td>Acetylsalicylic acid</td><td>The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid
is combined with Liraglutide.</td></tr><tr><td>L26</td><td>1</td><td>Liraglutide</td><td>Bisoprolol</td><td>The therapeutic efficacy of Liraglutide can be increased when used in
combination with Bisoprolol.</td></tr><tr><td>L26</td><td>1</td><td>Liraglutide</td><td>Dapagliflozin</td><td>Dapagliflozin may increase the hypoglycemic activities of Liraglutide.</td></tr><tr><td>L26</td><td>1</td><td>Liraglutide</td><td>Furosemide</td><td>The therapeutic efficacy of Liraglutide can be decreased when used in
combination with Furosemide.</td></tr><tr><td>L26</td><td>1</td><td>Liraglutide</td><td>Gliclazide</td><td>Liraglutide may increase the hypoglycemic activities of Gliclazide.</td></tr><tr><td>L26</td><td>1</td><td>Omeprazole</td><td>Gliclazide</td><td>The metabolism of Gliclazide can be decreased when combined with Omeprazole.</td></tr><tr><td>L26</td><td>1</td><td>Omeprazole</td><td>Raltegravir</td><td>Omeprazole can cause an increase in the absorption of Raltegravir resulting in
an increased serum concentration and potentially a worsening of adverse effects.</td></tr><tr><td>L26</td><td>1</td><td>Raltegravir</td><td>Atorvastatin</td><td>The risk or severity of myopathy and rhabdomyolysis can be increased when
Raltegravir is combined with Atorvastatin.</td></tr><tr><td>L26</td><td>1</td><td>Sacubitril</td><td>Acetylsalicylic acid</td><td>The risk or severity of angioedema can be increased when Acetylsalicylic acid is
combined with Sacubitril.</td></tr><tr><td>L26</td><td>1</td><td>Sacubitril</td><td>Atorvastatin</td><td>The excretion of Atorvastatin can be decreased when combined with Sacubitril.</td></tr><tr><td>L26</td><td>1</td><td>Sacubitril</td><td>Bisoprolol</td><td>The risk or severity of adverse effects can be increased when Bisoprolol is
combined with Sacubitril.</td></tr><tr><td>L26</td><td>1</td><td>Sacubitril</td><td>Tenofovir alafenamide</td><td>The serum concentration of Tenofovir alafenamide can be increased when it is
combined with Sacubitril.</td></tr><tr><td>L26</td><td>1</td><td>Silodosin</td><td>Bisoprolol</td><td>The risk or severity of orthostatic hypotension and dizziness can be increased
when Bisoprolol is combined with Silodosin.</td></tr><tr><td>L26</td><td>1</td><td>Silodosin</td><td>Furosemide</td><td>The risk or severity of orthostatic hypotension and dizziness can be increased
when Furosemide is combined with Silodosin.</td></tr><tr><td>L26</td><td>1</td><td>Tenofovir alafenamide</td><td>Acetylsalicylic acid</td><td>The serum concentration of Tenofovir alafenamide can be increased when it is
combined with Acetylsalicylic acid.</td></tr><tr><td>L26</td><td>1</td><td>Tenofovir alafenamide</td><td>Atorvastatin</td><td>The excretion of Tenofovir alafenamide can be decreased when combined with
Atorvastatin.</td></tr><tr><td>L26</td><td>1</td><td>Tenofovir alafenamide</td><td>Bisoprolol</td><td>The serum concentration of Tenofovir alafenamide can be increased when it is
combined with Bisoprolol.</td></tr><tr><td>L26</td><td>1</td><td>Valsartan</td><td>Acetylsalicylic acid</td><td>The risk or severity of renal failure, hyperkalemia, and hypertension can be
increased when Valsartan is combined with Acetylsalicylic acid.</td></tr><tr><td>L26</td><td>1</td><td>Valsartan</td><td>Atorvastatin</td><td>The excretion of Atorvastatin can be decreased when combined with Valsartan.</td></tr><tr><td>L26</td><td>1</td><td>Valsartan</td><td>Bisoprolol</td><td>Valsartan may increase the hypotensive activities of Bisoprolol.</td></tr><tr><td>L26</td><td>1</td><td>Valsartan</td><td>Dapagliflozin</td><td>The risk or severity of adverse effects can be increased when Valsartan is
combined with Dapagliflozin.</td></tr><tr><td>L26</td><td>1</td><td>Valsartan</td><td>Furosemide</td><td>The risk or severity of renal failure and hypotension can be increased when
Furosemide is combined with Valsartan.</td></tr><tr><td>L26</td><td>1</td><td>Valsartan</td><td>Gliclazide</td><td>The metabolism of Gliclazide can be decreased when combined with Valsartan.</td></tr><tr><td>L26</td><td>1</td><td>Valsartan</td><td>Insulin degludec</td><td>The risk or severity of hypoglycemia can be increased when Valsartan is combined
with Insulin degludec.</td></tr><tr><td>L26</td><td>1</td><td>Valsartan</td><td>Silodosin</td><td>The risk or severity of orthostatic hypotension and dizziness can be increased
when Valsartan is combined with Silodosin.</td></tr><tr><td>L26</td><td>1</td><td>Valsartan</td><td>Tenofovir alafenamide</td><td>The excretion of Tenofovir alafenamide can be decreased when combined with
Valsartan.</td></tr></tbody></table></div>
